Skip to main content
Veterinary Medicines

IZOVAC MAREK BIVALENTE

Authorised
  • Turkey herpesvirus, strain FC-126 (cell-associated), Live
  • Marek's disease virus, serotype 1, strain CVI-988 (Rispens), Live

Product identification

Medicine name:
IZOVAC MAREK BIVALENTE
Active substance:
  • Turkey herpesvirus, strain FC-126 (cell-associated), Live
  • Marek's disease virus, serotype 1, strain CVI-988 (Rispens), Live
Target species:
  • Chicken
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Turkey herpesvirus, strain FC-126 (cell-associated), Live
    2000.00
    plaque forming unit
    /
    1.00
    dose
  • Marek's disease virus, serotype 1, strain CVI-988 (Rispens), Live
    2000.00
    plaque forming unit
    /
    1.00
    dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Chicken
      • Meat and offal
        0
        day
      • Eggs
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD03
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Izo S.r.l.
Marketing authorisation date:
This information is not available for this product.
Manufacturing sites for batch release:
  • Izo S.r.l.
Responsible authority:
  • Ministry Of Health
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 13/03/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."